Pot plant Although a product suchas CBD may be marketed and sold legally, the FDA still has asignificant interest in making sure that it is done so inaccordance with its set guidelines. (Photo: Bloomberg)

One of the hottest topics in health care benefits today is theuse of medical marijuana products and how payers willdefine the parameters of how when such products are covered movingforward, as the law continues to evolve on the state and federallevel. With marijuana classified as a Schedule I drug at thefederal level (alongside unlikely neighbors such as heroin andpeyote) and now completely legal in numerous states even forrecreational use, the prospect of instituting any type of coveragefor cannabis products is risky to begin with.

However, we've still seen some payers communicate an interest indoing so, recognizing that from a cost containment perspective,medical marijuana may be a much better choice than the high costspecialty drugs it might be replacing in certain situations. Now,some changes at the federal level have cleared the way for coveringcertain types of marijuana-derivatives, without the risksassociated with reimbursement for a product the use of which iscriminal under federal law.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.